News
12-10-2010, 07:20 AM
The National Institute for Health and Clinical Excellence (NICE) has been asked to assess whether bevacizumab (Avastin, Roche Products), when used in combination with a taxane (a type of chemotherapy), would be a useful and cost-effective treatment option for people with breast cancer which has spread to other parts of the body...
More... (http://mnt.to/f/3NRG)
More... (http://mnt.to/f/3NRG)